Comparative Pharmacology
Head-to-head clinical analysis: BRANCHAMIN 4 versus BRANCHAMIN 4 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRANCHAMIN 4 versus BRANCHAMIN 4 IN PLASTIC CONTAINER.
BRANCHAMIN 4% vs BRANCHAMIN 4% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential branched-chain amino acids (leucine, isoleucine, valine) to correct deficiencies and support protein synthesis in catabolic states; serves as a substrate for energy production and muscle metabolism.
BRANCHAMIN 4% is a branched-chain amino acid (BCAA) solution providing leucine, isoleucine, and valine. It serves as a substrate for protein synthesis and energy metabolism in muscle tissue, particularly during stress or starvation. BCAAs regulate protein turnover by stimulating insulin secretion and mTOR signaling, thereby promoting anabolism and reducing catabolism.
1-1.5 g/kg/day intravenously, infused at a rate not exceeding 10 g/hour.
Intravenous infusion of 500 mL to 1000 mL per day, administered at a rate not exceeding 100 mL/hour. Typical dose: 7-10 mL/kg/day.
None Documented
None Documented
Terminal elimination half-life of individual amino acids ranges from 0.5 to 2 hours; clinical context: rapid clearance requires continuous infusion to maintain plasma levels
Branched-chain amino acids (BCAAs) have short half-lives: leucine ~0.5-2 h, isoleucine ~1-2 h, valine ~1-2 h. In hepatic impairment, half-life may be prolonged.
Primarily renal; >90% of infused amino acids are excreted in urine as metabolites (urea, ammonia) within 24 hours; minimal biliary/fecal elimination (<5%)
Renal elimination of infused amino acids; negligible biliary/fecal excretion. Typically >90% of infused nitrogen is excreted renally as urea and ammonia.
Category C
Category C
Amino Acid Supplement
Amino Acid Supplement